Skip to main content

Table 3 Univariate analysis of the risk factors for CSS (N = 57)

From: High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer

Variables

Univariate analysis

HR (95% CI)

p value

Log-rank p

Age (< 60 vs. ≥ 60)

1.308 (0.292–5.855)

0.725

0.725

Gender (male vs. female)

1.657 (0.309–8.888)

0.555

0.551

AJCC/UICC stage

  

0.573

 I

Reference

0.603

 

 II

0.327 (0.02–5.240)

0.429

 

 III

0.966 (0.110–8.457)

0.975

 

Length (< 5 vs. ≥ 5 cm)

1.308 (0.292–5.855)

0.725

0.960

Histopathology

  

0.629

 Poorly differentiated

Reference

0.641

 

 Moderately differentiated

1.022 (0.105–9.920)

0.985

 

 Undefined

2.089 (0.216–20.179)

0.524

 

CEA levels (< 5 vs. ≥ 5 ng/ml)

1.483 (0.329–6.689)

0.608

0.606

Distance to the anal verge (< 5 vs. ≥ 5 cm)

0.432 (0.051–3.645)

0.441

0.428

Courses of radiotherapy (one course vs. two course)

1.075 (0.129–8.980)

0.946

0.946

Chemotherapy regime (Capecitabine vs. Capoex/folfox)

1.005 (0.195–5.187)

0.996

0.996

Cycles of chemotherapy (≤ 4 vs. > 4)

2.052 (0.241–17.441)

0.510

0.502

Response to treatment (cCR vs. non-cCR)

6.361 (1.380–29.328)

0.018

0.007*

Comorbidities (yes vs. no)

39.757 (0.033–48,411.962)

0.310

0.083

  1. CSS cancer specific survival, HR hazard ratio, AJCC/UICC American Joint Committee on Cancer/International Union Against Cancer, CEA carcinoembryonic antigen, cCR clinical complete response
  2. *Statistically significant